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Abstract  
AIM: Prompt discovery of allosensibilisation to RBC’s antigens during pregnancy and successful 
management of HDFN in Republic of Macedonia, in order to decrease morbidity and mortality of the 
fetus and the newborn. 
MATERIALS AND METHODS: The study comprises in total 23,800 patients, 14,858 pregnant 
women and 8,842 newborn babies.  
 
RESULTS: The screening and identification of anti RBC’s antibodies detected in total 216 
alloantibodies, out of which 81% (175) had a clinical significance. Out of the above mentioned 164 
alloantibodies (65.9%) belong to the Rh system. The most often reason for a severe hemolytic 
disease is the anti-D antibody. The HDFN symptoms of mild and moderate degree demonstrated 
32.5%, and 18.9% had symptoms of severe fetal suffering, and almost half of them (48%) were with 
or with mild HDFN and had no need of therapy. In 15% it was about alloantibodies of other Rg 
antigens: anti-C, anti-E and anti-c, at which in most cases there were no signs of HDFN, or it 
showed weak symptoms (89%), just one case of anti-c ended with intrauterine death.  
CONCLUSIONS: Anti D antibody represents the most often reason for severe HDFN and displays 
a need of intrauterine transfusion and exsangvino transfusion. Anti-c is the only antibody that 
demonstrated the same potential for severe HBN as the anti-D. The most often reason for 
alloimmunisation of the mother is the lack of RhIG prophylaxis (97.8): postnatal, antenatal and in 
case of possible sensible conditions during pregnancy. Thus, there is a need and an outmost 
importance of elaboration and adoption of the National programe for RhIG prophylaxis in Republic 
of Macedonia. 
 
 
 
 
 
Introduction 
The hemolytic disease of the fetus and the 
newborn (HDFN) is a clinical syndrome at which the 
basic patho-physiological disorder represents a 
hemolytic anemia of the fetus or the newborn. HDFN 
starts during the intrauterine life, and the cause of the 
disease is the presence of IgG antibodies that appear 
as a result of aloimunization of the mother towards the 
Red Blood Cells (RBC) antigens of the fetus, inherited 
from the father, and not present in the mother. 
It is directly dependant of the development of 
RBC’s antigens on the surface of fetal RBC. The 
RBC’s membrane of the newborn does not comprise 
in full development of all antigens that are present in 
adult’s RBC. The antigens whose specific 
characteristics are determined by imunomodulator 
sugar components (ABH, Lewis, P, Sd
a
) are not well 
developed immediately after birth, compared to 
protein antigens (Rh, MNS, Duffy, Kell, Kid), which are 
completely present. A and B antigens can be proven 
at an embryo as soon as the 5-6 gestation week, but 
after birth their expression is only at 50%, because of 
lack of the H-substance as a substract on which the 
enzymes work for creation of additional 
imunodominant sugar components. I and Lewis 
antigens are fully developed at the 18
th
 month of the 
newborn after birth [1]. In comparison, the D antigen 
can be tested/proven as soon as the 38
th
 gestation 
day, and it is well developed after birth [2]. RBC’s 
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antigens at a newborn [1] and the level of their 
presence can be divided into three groups: 
 RBC’s antigens that are well developed at the 
newborns’ RBC: Diego, Dombrock, Duffy, 
En
a
, Gerbrich, Kell, Kidd, MNSs, Rh, 
Sciannia, Yt
b
 
 RBC’s antigens that exist on the newborns’ 
RBC’s membrane, but are less expressed 
compared to adult’s erythrocytes: ABH, 
Lutheran, P, Xga 
 RBC’s antigens that are much less expressed 
or completely absent at the newborns’ RBC: 
Chido, Rogers, I, Lewis, Sd
a
, Vel, Yt
a
 
The diseases’ pahto-physiology is connected 
to the transfer of antibodies from the mother to the 
fetus which is done exclusively through the placenta. 
At the same time, the placenta is an imunologic 
barrier where the trophoblast rich with sialin acid, 
besides the IgG antibodies, lets in and out only certain 
cell elements in both directions. 
RBC, Platelet and WBC of the throphoblast 
and imunoglobulines pass from the fetus towards the 
mother, and from the mother to the fetus pass only the 
mother’s RBC, Platelet and IgG. The only 
immunoglobulin transfer is the one of the IgG 
antibodies that get tied to the Fc receptor of the 
placenta’s plasma membrane as an active transport 
that goes on in only one direction from the mother to 
the fetus and never vice versa [3]. 
It should be especially emphasized that the 
fagocites of the fetus for IgG anti-bodies, there are 
FcyRI receptors that are responsible for hemolysis of 
RBC coated with antibodies [4, 5]. The immunization 
of the mother will take 0.1ml of fetal RBC. The 
frequency of transplacenta hemorrhage is directly 
dependant on the gestation week and increases 
further on during pregnancy. 
There are more factors known that influence 
the destruction of IgG sensibilized RBC, determining 
the strength of HDFN: special characteristics of 
alloantibodies, concentration of alloantibodies, IgG 
glycolization, IgG subclasses; antigen density of 
erythrocytes, structure, tissue (placenta) distribution; 
the function of the fetal spleen, FcR polymorphism, 
inhibiting antibodies, fetal abgar. The most important 
information that demonstrates potential clinic 
significance of anti RBC’s alloantibodies at HBN is 
their distinctiveness. 
Accordingly, one of the reasons for habitual 
abortions, fetal death, as well as premature birth with 
symptomes of severe hemolitical disease at newborns 
is the alloimmunization of the mother to RBC’s 
antigens. 
One of the primary goals of immuno-
hemathological testing as a part of antenatal testing to 
HDFN is to provide clinically valid information to the 
cooperation team (gynecologist – obstetrician), in the 
true sense of the word “cost effect”. The validity of 
information comprises determination of need and 
exact time to begin with invasive monitoring of HDFN 
– amniocentesis, cordocentesis – with a risk of 
transplacental hemorrhage, exacerbation of 
alloimmunization and increase of fetal anemia, and a 
need of Intra Uterine Transfusion. Thus, immune-
hematological testing can greatly contribute in 
avoidance of this risk.  
Table 1: A probability for serious HDFN associated to anti-RBC 
antibodies (A. F. Eder) [18]. 
Blood type 
system 
The biggest 
probability 
for severe 
Rare cases of 
severe HBN 
Most often 
associated to 
moderate 
severity 
Do not 
cause HBN   
MNS  
M, S, s, U, Mi
a
, 
Hut,  
Mur, Mt
a
, Hil, 
M
v
, Far, sD, 
MUT 
M, S, s, U,  
Mt
a  
Mit 
N 
Rh D, c 
C, E, f, Ce, C
w
, 
C
x
, E
w
,  
G, Hro, Hr, 
Rh29, Go
a
,  
Rh32, Be
a
, 
Evans, Tar,  
Rh42, Sec, 
JAL, STEM 
E, e, f, C
x
, D
w
, 
Rh29, Riv, 
LOCR 
 
Luteran   Lu
a
(rare), Lu
b
  
Kell K 
k, Kp
a
, Kp
b
, 
Ku, Js
a
, Js
b
,  
UI
a
,K11, K22, 
Ku, Js
a
,K11 K23, K24 
Lewis     Le
a
, Le
b
 
Dufy  Fy
a
 
Fy
b
(rare), 
Fy3(rare) 
 
Kidd  Jk
a
 Jk
b
(rare), Jk3  
Others 
 
 
 
 
 
 
 
 
 
Di
a
, Wr
a
, Rd, 
Co
a
, 
Co3, PP1P
k
, 
Vel, 
MAM 
Bi, Kg, 
JONES, 
HJK, REIT 
Di
b
, Sc3, Co
b
, 
Ge2, Ge3, Ls
a
, 
Lan, At
a
, Jr
a
, 
LFV, HOFM 
 
P1, Wr
b
, Yt
a
, 
Yt
b
, 
Sc1, Sc2, 
CH/RG 
CROM, KN, 
I, 
JMH, Jr
a
,     
HLA: Bg
a
, 
Bg
b
, Bg
c
 
 
  
Materials and Methods 
The study comprises in total 23,800 patients, 
14,858 pregnant women and 8,842 newborn babies, 
during a period of 8 years. 
The immune-hematological testing for all 
pregnant women has been executed in the immune-
hematology laboratory at the Institute for Transfusion 
Medicine in Republic of Macedonia. The tests have 
been executed in the serum and RBC of vein blood, 
without anticoagulant and/or EDTA, not older than 24 
hours. 
The immune-hematological testing for 
newborn babies has been executed of vein and 
umbilical blood, without anticoagulant and/or EDTA, 
not older than 24 hours. 
The immune-hematological testing that are 
used in this study: 
 blood type typization of RBC’s antigens; 
 screening and irregular anti-RBC’s antibodies 
(IAT, enzyme test and DAT). 
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Testing that has been applied to patients with 
positive screening tests: 
 identification of anti-bodies with commercial 
panels for all patients; 
 elution of antibodies; 
 titer of anti-bodies (salty, Coombs and 
enzymes’ tests). 
 
Statistic methods 
During the process of research acquired data 
are statistically elaborated with the following statistic 
methods: 
- Statistic series according all defined 
variables of interest, displayed in tables and 
graphs; 
- Analysis of the structure of attributive 
statistic series has been done by coefficient of 
relations, proportions and rates; 
- Testing of difference significance between 
two proportions has been done by the 
Students test of proportions. 
 
Hemolytic disease of a newborn baby in 
correlation with immuno-hematological 
analysis 
All blood samples taken from pregnant 
women, where immuno-hematological analysis 
demonstrated positive results, incited continuous 
immuno-hematological testing of the mother during 
pregnancy (every 2-3 weeks) and follow up of the fetal 
development on the Clinic for Gynecology and 
Obstetrics – Skopje, on the ward for pathology 
pregnancy. All newborn babies of sensibilized 
mothers were treated according a special monitoring 
for at least five days on the ward for pediatrics in 
CGO. In total 216 alloantibodies were discovered, out 
of which 164 belong to the Rh system. The results 
have shown that the most often reason for a severe 
hemolytic disease is anti-D antibody in 51.4 % of the 
total number of alloantibodies, or in 80.4% of the 
cases with Rh sensibilization. 32.5% of the 
sensibilizations related to this antigen showed 
symptoms of HDFN with moderate and serious range, 
and a need of phototherapy and/or exsangvino 
transfusion. In 18.9% were shown symptoms of 
severe fetal suffering, demonstrated by hidrops fetalis 
or fetal death.  
Almost half (48%) of the D positive newborns 
from mothers that have a detected anti D antibodies 
were without or with a mild HBN and had no need for 
therapy.  
The rest of the Rh anti erythrocyte antibodies 
that do not belong to anti-D and are most frequent 
are: anti-E and anti-C. Out of 8 patients anti-E only 1 
needed therapy (phototerapy. They rarely give a 
strong demonstration of HBN. 
Anti-C is the only antibody that showed the 
same potential for severe HBN as the anti-D with a 
fetal hidrops. When a presence of anti-C antibody is 
detected the possibility to cause HBN is higher (44%), 
than anti-E (12.5%), and in these cases most often an 
exsangvino transfusion or phototherapy is needed 
(33%), than at the anti-E (10%). 
The comparison of sympthoms and therapy at 
newborns with immuno-hematology research of their 
mothers has been shown on the Table 2.  
Table 2: Distribution of antierythrocyte antibodies and the 
severity of the clinical picture of HBN in Republic of 
Macedonia. 
Aloantibodies Sensibilized 
No 
therapy 
Phototherapy, 
exsangvino 
IUT, hidrops 
Hb<60г/л 
D 132 64 (48%) 43 (32.5%) 25 (18.9%) 
C 13 9 (69%) 4 (31%) 0 
c 9 5 (55%) 3 (33%) 1 (11%) 
E 10 9 (90%) 1 (10%) 0 
Total 164 87 (53%) 51 (32%) 26 (15.8%) 
 
There was a research of the reasons for 
appearance of alloimmunization at pregnant women. 
The most frequent reason is a lack of RhIG 
prophylaxis: post partum in 69.2% and during 
pregnancy in possible sensibilized conditions 28.6%. 
In 3.2% of the cases we acquired a data for post 
partum prophylaxis, in cases of not executed 
antenatal prophylaxis, and there is no data for a 
sensibilised attack. 
 
Discussion 
Severe HDFN is almost always caused by 
antigens with a protein biochemical structure. These 
antigens develop in the IVth month of pregnancy. 
Thus, for example, antigen D can be proved present 
on the erythrocyte membrane on the 38
th
 day of 
gestation, which enables early primary and especially 
secondary immunization of the mother by creating anti 
RBC’s antibodies of IgG class [2]. 
According literature data, the percentage of 
RhD alloimmunization during pregnancy has declined 
from 14% to 1% and 2% after introduction of postnatal 
prophylaxis with Rh immunoglobulin (RhIG) in 1960. 
This percentage globally further on declined to 0.1% 
with implementation of additional antenatal RhIG 
prophylaxis in 1979 [6, 7]. 
Still, a hemolytic disease of the fetus and the 
newborn caused by anti-D is one of the most often 
reason for HDFN in most underdeveloped countries in 
the world. The results acquired from most of the 
studies demonstrate that around 80% of HDFN 
belongs to RhD antibodies, or in combination with 
other antibodies of the Rh system 96.5% [7, 8]. In 
around 12% it is about antibodies towards other Rh 
antigens, mostly E and c [15]. The rest of the 
antibodies are towards Kell and Kid blood type 
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systems [13, 14]. It is well known that the strength of 
HDFN varies according the characteristics of the 
antibodies, their amount and exposition on the fetus. 
Out of the outmost importance are the subclasses of 
IgG antibodies, that with the mother are most often of 
IgG2 class and do not cause lysis of Foethal RBC, 
which explains the fact that 53% of the D antigen 
allosensibilisation demonstrate no signs of HDFN, or it 
shows very weak symthoms. However, IgG1 and IgG3 
subclasses, especially when present together, display 
a clinical picture of severe HDFN. 
Allosensibilization to the RhD antigen during 
pregnancy requires invasive monitoring and treatment 
during the period of the whole pregnancy. 
Unfortunately, that does not exclude the possibility of 
unsuccessful pregnancy finish and the severity of the 
HDFN symptoms increases with every following 
pregnancy. Literature data show that by successful 
management, 86-90% of allosensibilized pregnancies 
reach to survival in the neonatal period [9, 10]. Data 
from CESDI for England and Ireland display that the 
fetal loss because of RhD sensibilization amounts 15-
17% to 24 gestation week, and premature birth is 
about 35-48%. 
There are two reasons why RhD 
immunization and sensibilization at pregnant women 
appear. Firstly, there is a lack of RhIG administration 
or inadequate prenatal protection, because all RhD 
negative women do not get anti-D immunoglobulin 
when necessary. Secondly, the reason is an 
occurrence of small, undetectable (“silent”) 
fetomaternal bleedings in the third trimester of 
pregnancy [16, 17]. 
The quantification of the antibodies was 
executed by titer in all samples that have shown 
positive screening and identification to anti-RBC’s 
antibodies. The Titer score elaborated by a 
microglutination test (MT) was at least two dissolution 
rates higher compared to the test-tube technique (TT-
LISS).  
The titer antibody is not a precise method, 
and can be useful only if executed in standard 
conditions and by an experienced staff. There are 
more standard methods for quantification of anti-
RBC’s alloantibodies: ELISA, flowcytometry, 
radioimmunoassay, that is not used as a routine [11]. 
In order to determine the border line titer in case of 
possible fetal suffer and correlation of alloantibodies 
titer with the severity of HDFN, additional research are 
needed which have not been included in this research 
study. So far, we should mention that the titer level of 
alloantibodies has a clinical significance only in the 
first pregnancy when the sensibility occurred. 
Following the titer rate in the next pregnancy is 
irrelevant, while a significant importance is shown by a 
sudden raise of titer for 2 or more dissolutions which 
implies significant changes and requires more detailed 
analysis [12]. 
The border line titer in case of possible fetal 
anemia, according scientific research is 1:34 (1:62) for 
ТТ-LISS and 1:16 for МТ (because of the fact that the 
titer in МТ are 2 to 3 times higher dissolutions) which 
is particularly subjective, since MT has relevant values 
and each increase requires additional explanation. 
 
Conclusions 
1. The comparison of HDFN symptoms and 
therapy of newborn babies with immunohemolitic 
research has proven that: 
 53% of the antibodies did not provoke HDFN 
or it had mild symptoms and no need of 
therapy; 
 51% provoked moderate HDFN; 
 15.8% provoked HDFN with clinical signs of 
severe anemia, hidrops and fetus mortus. 
2. Out of total 216 alloantibodies, 81% (175) had 
clinical significance. 
3. The most frequent reason for severe hemolytic 
disease is the anti-D antibody in 61.1% of the cases. 
Out of them: 
 32.5% of the sensibilized to this antigen 
showed symptoms of moderate and severe 
rate of HDFN, with a need of phototherapy 
or/and exsangvino transfusion; 
 18.9%showed symptoms of severe fetal 
suffer, with a hydropic or dead fetus; 
 Almost half (48%) of the D positive newborns 
of mothers with detected anti-D antibodies 
were without, or with a mild HDFN and had no 
need of therapy. 
4. In 15% of the cases it is about alloantibodies of 
other Rh antigens, mostly anti-C 7.8%, anti-E 6% and 
anti-c 5.4%. 
5. Anti-c is the only antibody that showed a potential 
for severe HDFN similar to the anti-D. 
6. Most frequent reason for alloimmunization of the 
mother is the lack of RhIG prophylaxis (97.8%): 
postnatal, antenatal and in case of possible 
sensibilized conditions during pregnancy. 
7. It is necessary to elaborate and adopt a national 
program for RhIG prophylaxis in Republic of 
Macedonia. 
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